Physiology and Pharmacology Publications
Document Type
Article
Publication Date
6-1-2020
Journal
Critical Care Exploration
Volume
2
Issue
6
First Page
0144
Last Page
0144
URL with Digital Object Identifier
doi: 10.1097/CCE.0000000000000144
Abstract
Objectives: Coronavirus disease 2019 is caused by severe acute respiratory syndrome-coronavirus-2 infection to which there is no community immunity. Patients admitted to ICUs have high mortality, with only supportive therapies available. Our aim was to profile plasma inflammatory analytes to help understand the host response to coronavirus disease 2019.
Design: Daily blood inflammation profiling with immunoassays.
Setting: Tertiary care ICU and academic laboratory.
Subjects: All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome-coronavirus-2, using standardized hospital screening methodologies, had daily blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative), or until ICU day 7 if the patient was positive (coronavirus disease 2019 positive).
Interventions: None.
Measurements and Main Results: Age- and sex-matched healthy controls and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients were more likely than coronavirus disease 2019 negative patients to suffer bilateral pneumonia. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. We measured 57 inflammatory analytes and then analyzed with both conventional statistics and machine learning. Twenty inflammatory analytes were different between coronavirus disease 2019 positive patients and healthy controls (
Conclusions: While many inflammatory analytes were elevated in coronavirus disease 2019 positive ICU patients, relative to healthy controls, the top six analytes distinguishing coronavirus disease 2019 positive ICU patients from coronavirus disease 2019 negative ICU patients were tumor necrosis factor, granzyme B, heat shock protein 70, interleukin-18, interferon-gamma-inducible protein 10, and elastase 2.
Citation of this paper:
Fraser, Douglas D. MD, PhD1,,2; Cepinskas, Gediminas DVM, PhD1,,3; Slessarev, Marat MD, MSc1,,4; Martin, Claudio MD, MSc1,,4; Daley, Mark PhD1,,5,,6; Miller, Michael R. PhD1,,2; O’Gorman, David B. PhD1,,7; Gill, Sean E. PhD1,,4,,8; Patterson, Eric K. PhD1; dos Santos, Claudia C. MD, MSc9,,10; on behalf of the Lawson COVID-19 Study Team Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients, Critical Care Explorations: June 2020 - Volume 2 - Issue 6 - p e0144 doi: 10.1097/CCE.0000000000000144
Notes
Copyright © 2020 The Authors.